Lexaria Bioscience is a pioneering brand that specializes in patented drug delivery technology called DehydraTECH. This innovative technology revolutionizes the way active pharmaceutical ingredients (APIs) enter the bloodstream, resulting in more effective oral delivery. Through extensive testing, DehydraTECH has been proven to enhance bio-absorption with cannabinoids and nicotine by 5-10 times, and in some cases, even up to 17 times when compared to standard industry formulations.

It also significantly reduces the onset time from 1-2 hours to mere minutes and masks unwanted tastes. Lexaria Bioscience is actively exploring the application of DehydraTECH in various fields, including hypertension, oral nicotine, antiviral drugs, epilepsy, and more. With an impressive intellectual property portfolio consisting of 35 granted patents and numerous pending patents worldwide, Lexaria Bioscience is committed to advancing drug delivery systems and improving the efficacy of ingestible drugs.

They operate four subsidiary companies, each focusing on different commercial opportunities within their respective industries. Lexaria Bioscience continues to lead the way in the development and licensing of their groundbreaking DehydraTECH technology